{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:22:05Z","timestamp":1732857725192,"version":"3.30.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,28]]},"DOI":"10.7759\/cureus.74649","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:31:48Z","timestamp":1732789908000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring Public Interest in Multiple Sclerosis and Its Treatment Measures in the United States: A Google Trends Analysis"],"prefix":"10.7759","author":[{"given":"Zaed S","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidith","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf-Zain A","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaskaran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai K","family":"Angadala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pruthvi Sai Chowdary","family":"Aluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya S","family":"Puvvada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Deoghare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich DS","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018, 378:169-80. 10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"ref2","article-title":"Multiple sclerosis","author":"Tafti D","year":"2024","unstructured":"Tafti D, Ehsan M, Xixis KL. Multiple sclerosis. StatPearls [Internet]. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/her\/cyn004","article-title":"Understanding tailoring in communicating about health","volume":"23","author":"Hawkins RP","year":"2008","unstructured":"Hawkins RP, Kreuter M, Resnicow K, Fishbein M, Dijkstra A. Understanding tailoring in communicating about health. Health Educ Res. 2008, 23:454-66. 10.1093\/her\/cyn004","journal-title":"Health Educ Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v4.i3.27","article-title":"Multiple sclerosis and the role of immune cells","volume":"4","author":"H\u00f8glund RA","year":"2014","unstructured":"H\u00f8glund RA, Maghazachi AA. Multiple sclerosis and the role of immune cells. World J Exp Med. 2014, 4:27-37. 10.5493\/wjem.v4.i3.27","journal-title":"World J Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban X","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al.. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017, 376:209-20. 10.1056\/NEJMoa1606468","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-023-01344-6","article-title":"The use of stem cells as a potential treatment method for selected neurodegenerative diseases: Review","volume":"43","author":"Cecerska-Hery\u0107 E","year":"2023","unstructured":"Cecerska-Hery\u0107 E, P\u0119ka\u0142a M, Serwin N, et al.. The use of stem cells as a potential treatment method for selected neurodegenerative diseases: Review. Cell Mol Neurobiol. 2023, 43:2643-73. 10.1007\/s10571-023-01344-6","journal-title":"Cell Mol Neurobiol"},{"key":"ref7","unstructured":"Google Trends. (2024). Accessed. May 17, 2024: https:\/\/trends.google.com\/trends\/."},{"key":"ref8","article-title":"Infodemiology: Tracking flu-related searches on the web for syndromic surveillance","volume":"2006","author":"Eysenbach G","year":"2006","unstructured":"Eysenbach G. Infodemiology: Tracking flu-related searches on the web for syndromic surveillance. AMIA Annu Symp Proc. 2006, 2006:244-8.","journal-title":"AMIA Annu Symp Proc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2196\/13439","article-title":"Google trends in infodemiology and infoveillance: Methodology framework","volume":"5","author":"Mavragani A","year":"2019","unstructured":"Mavragani A, Ochoa G. Google trends in infodemiology and infoveillance: Methodology framework. JMIR Public Health Surveill. 2019, 5:e13439. 10.2196\/13439","journal-title":"JMIR Public Health Surveill"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser SL","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al.. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017, 376:221-34. 10.1056\/NEJMoa1601277","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy","volume":"87","author":"Salzer J","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, et al.. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology. 2016, 87:2074-81. 10.1212\/WNL.0000000000003331","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos L","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, et al.. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010, 362:387-401. 10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2022.09.006","article-title":"Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice","volume":"179","author":"Bourre B","year":"2023","unstructured":"Bourre B, Casez O, Ciron J, et al.. Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice. Rev Neurol. 2023, 179:256-64. 10.1016\/j.neurol.2022.09.006","journal-title":"Rev Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi G","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, et al.. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019, 18:1009-20. 10.1016\/S1474-4422(19)30239-X","journal-title":"Lancet Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement","volume":"62","author":"Freedman MS","year":"2005","unstructured":"Freedman MS, Thompson EJ, Deisenhammer F, et al.. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol. 2005, 62:865-70. 10.1001\/archneur.62.6.865","journal-title":"Arch Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study","volume":"391","author":"Kappos L","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al.. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet. 2018, 391:1263-73. 10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/316779-exploring-public-interest-in-multiple-sclerosis-and-its-treatment-measures-in-the-united-states-a-google-trends-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T10:31:50Z","timestamp":1732789910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/316779-exploring-public-interest-in-multiple-sclerosis-and-its-treatment-measures-in-the-united-states-a-google-trends-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74649","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}